HA 132
Alternative Names: Cisplatin micelle - CSPC Zhongqi Pharmaceutical Technology; Cisplatin micelle injection; HA-132Latest Information Update: 13 Aug 2026
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Mar 2025 Phase-I clinical trials in Solid tumours in China (Parenteral)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral, Injection)
- 31 Aug 2022 CSPC ZhongQi Pharmaceutical Technology plans a phase I/II trial for Solid tumours (Late-stage disease, Recurrent, Metastatic disease) in China (IV, Injection) in August 2022 (NCT05478785)